Sheng Lin-Gibson NIST

Dr. Sheng Lin-Gibson is the Chief of the Biosystems and Biomaterials Division (BBD) at the National Institute of Standard and Technology (NIST).  BBD has a multidisciplinary technical portfolio that includes genomic measurements, synthetic biology, regenerative medicine and advanced therapies, biomaterials, diagnostics, and complex microbial systems. BBD carries out its mission through fundamental research in measurement science, the development of new technologies, and the deployment of new measurement solutions, including reference materials and data. She serves as the Chairperson of the U.S. Technical Advisory Group (TAG) to ISO/TC 276: Biotechnology as well as the Convenor of ISO/TC 276 Working Group 3: Analytical Methods. She leads or contributes to the development of several international standards particularly relevant to cell and gene therapy manufacturing and characterization. Dr. Lin-Gibson is the NIST lead of various joint NIST/SCB efforts to coordinate the development of standards for regenerative medicine. She co-chairs the Multi-Agency Tissue Engineering Science (MATES) Working Group, an ad hoc interagency group that ensures communication and coordination of US Federal Agencies. She has coauthored over 80 peer-reviewed publications, served on numerous NSF, NIH, and NIST expert review panels, and is a recipient of three US Department of Commerce Bronze Medals.